PepEvolutionOrforglipron
The first oral non-peptide GLP-1 agonist nearing approval — pill convenience without injection, but not yet on market.
Verdict — C · Emerging / Mixed
Compelling phase-3 efficacy and the transformative advantage of oral dosing, but no approval yet and no verified supply outside a clinical trial. A C today that could become an A upon approval — do not source gray-market.
Overview
Orforglipron (Eli Lilly) is an oral small-molecule GLP-1 receptor agonist in late-stage ATTAIN trials, demonstrating ~15% weight loss in phase-3 data. Its oral formulation eliminates the injection burden of peptide GLP-1s. However, it has not yet received FDA approval, and no commercially available or verified gray-market supply exists — all circulating material should be treated as unverified research chemicals.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.